Creative Planning Purchases 4,937 Shares of Glaukos Co. (NYSE:GKOS)

Creative Planning raised its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 64.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,643 shares of the medical instruments supplier's stock after buying an additional 4,937 shares during the period. Creative Planning's holdings in Glaukos were worth $1,647,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after purchasing an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter worth approximately $187,000. Brighton Jones LLC acquired a new position in shares of Glaukos in the 2nd quarter worth approximately $208,000. Procyon Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter worth approximately $210,000. Finally, Mount Yale Investment Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter worth approximately $212,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at $13,216,581.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,250 shares of company stock worth $4,825,873 over the last ninety days. 6.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on GKOS shares. Piper Sandler set a $140.00 price objective on shares of Glaukos in a research note on Thursday, October 17th. Stifel Nicolaus lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Morgan Stanley lifted their target price on shares of Glaukos from $100.00 to $120.00 and gave the stock an "equal weight" rating in a research report on Monday, July 15th. Needham & Company LLC lifted their target price on shares of Glaukos from $131.00 to $137.00 and gave the stock a "buy" rating in a research report on Thursday, August 1st. Finally, Citigroup downgraded shares of Glaukos from a "buy" rating to a "neutral" rating and lifted their target price for the stock from $130.00 to $132.00 in a research report on Wednesday, July 10th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $130.45.

Glaukos Stock Up 0.7 %

Shares of GKOS stock traded up $0.99 during trading on Wednesday, hitting $138.74. 449,533 shares of the company were exchanged, compared to its average volume of 568,826. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of -48.05 and a beta of 1.02. The business's 50-day simple moving average is $129.48 and its 200 day simple moving average is $118.94. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $139.51.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, hitting the consensus estimate of ($0.52). The business had revenue of $95.70 million during the quarter, compared to analysts' expectations of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm's quarterly revenue was up 19.0% compared to the same quarter last year. During the same period last year, the company posted ($0.55) earnings per share. As a group, analysts forecast that Glaukos Co. will post -2.16 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.